O K , here is transcript with Tyler Blok explanation about our patents .
" So the two most common questions that we get when people ask about IP, and I'm just going to assume this is what people would want to hear by way of an update , is what exactly started to expire by way of IP in 2023, and then generally they want an assurance that the company has some sort of plan, right , or an idea , or is monitoring IP.
So as to the first, in terms of what started to expire in 2023 , the company is very cognizant of what expires and when.
Needless to say , we are a pre-revenue biotech company developing a single molecule . ...........
....................................
....................................
So the underlying molecule of the leronlimab antibody itself started to expire in 2023.
So that is foundational leronlimab .
You heard Jay speak earlier about how long he's been working with the antibody , right ?? There is IP tied to that.
So , as the longer the random at itself has been out in , the IP can only last so long as to the underlying antibodies,
Now , what the company does to build out the next levels of protection is we've gotten IP around the concentrated protein formulation , and those don't start to expire until 2031.
---We've gotten levels of IP protection surrounding the use of leronlimab and the treatment of HIV . That wont start to expire until 2035.
---We have method of action associated with cancer indication and methods of use and those start to expire in 2040.
---And then Covid , we have certain protections that again would start to expire in 2040.
---And then the most recently developed IP surrounding NASH would not even start to expire in 2043.
So , our approach to that IP and what technically started to expire would allow people to use leronlimab antibody for research purposes.
But the practical reality is we we've build up adequate protections around the applications of leronlimab and HIV , Covid , NASH ,
And then there's also some certain methods of action IP that would prevent antibody from substantially competing with us while using the wrong amount of antibodies "
Bullish
